§ Claim under review · Mixed
"For the first time, a drug designed to trigger the growth of new teeth in humans has entered human clinical trials. The treatment works by targeting a protein called USAG-1... In laboratory experiments, researchers successfully stimulated the growth of entirely new teeth simply by blocking this protein... Scientists also believe humans may genetically possess 'third tooth buds' hidden within the jaw..."
Verdict
Mostly accurate
Confidence
HighSummary
This claim is mostly accurate. A Japanese team at Kyoto University Hospital, led by Dr. Katsu Takahashi, did begin a first-in-human Phase 1 clinical trial in autumn 2024 for an antibody drug that blocks the USAG-1 protein, based on published animal research showing new tooth growth in mice and ferrets. The "third set of teeth" idea is a real scientific hypothesis under investigation, not settled fact. The post glosses over two important details: the "laboratory experiments" that grew new teeth were in animals, not humans, and the current human trial is a small safety study in 30 adult men, not a test of whether people can actually regrow teeth. Public availability, if the drug ever reaches that stage, is targeted for around 2030 at the earliest. Nothing in the claim is fabricated, but readers should treat it as a promising early-stage research story rather than a confirmed medical breakthrough.
The readings
key figures from the evidencePhase 1 trial size (healthy adult males, age 30-64)
Doses needed to stimulate tooth formation in animal studies
Earliest target year for public availability if trials succeed
Why this verdict
Evidence
Japanese scientists have initiated clinical trials for a groundbreaking drug that could enable humans to regrow missing or damaged teeth by targeting the USAG-1 protein. The therapy works by suppressing USAG-1, a protein that limits tooth growth.
In October 2024, researchers at Kyoto University Hospital in Japan commenced human trials for a novel drug designed to stimulate the growth of new teeth.
The initial phase involves 30 healthy adult males aged 30 to 64, each of whom is missing at least one tooth. The primary goal is to assess the safety of the drug and determine the appropriate dosing.
His team has discovered that humans possess dormant tooth buds, a third set of teeth that typically remain undeveloped. Their research pinpointed a protein, USAG-1, which inhibits these buds from forming.
Animal evidence: In a 2021 study, the company demonstrated that its neutralizing antibody can suppress a protein, dubbed USAG-1, which inhibits the growth of tooth buds. Prior published research in mice and ferrets showed that a single systemic administration of the anti-USAG-1 antibody could stimulate tooth formation.
Findings
✓ What's accurate 9
- A first-in-human clinical trial of a USAG-1-blocking antibody drug has begun at Kyoto University Hospital (autumn 2024).
- USAG-1 is a real protein (also known as SOSTDC1) that inhibits BMP signaling involved in tooth development.
- Animal experiments (mice, ferrets) did successfully produce new tooth growth after USAG-1 was blocked.
- The "third tooth bud" idea (dormant tooth germs beyond primary and permanent sets) is a real scientific hypothesis under active investigation.
- The Popular Mechanics link cited in the post is a legitimate outlet that has covered this research. ## WHAT IS MISLEADING OR OVERSIMPLIFIED
- **Omitted qualifier (species):** The post says "in laboratory experiments, researchers successfully stimulated the growth of entirely new teeth." The evidence is from **mice and ferrets**, not human laboratory subjects. This is species extrapolation without labeling.
- **Omitted qualifier (trial phase and scope):** The current trial is Phase 1 safety testing in 30 adult males, not a trial designed to demonstrate tooth regrowth in humans. The post implies the trial itself will demonstrate tooth regrowth.
- **Framing overreach:** "A real living tooth with a natural root and biological connection to the jawbone" describes the aspiration/animal result, not any confirmed human outcome.
- **"For the first time":** Broadly defensible, but this is the first Phase 1 trial of this specific antibody approach; earlier tooth-regeneration research (stem cell, tissue engineering) has also been explored in humans in other contexts.
? What's uncertain 3
- Whether the Phase 1 trial will demonstrate any tooth growth signal, or only safety data. Results have not been published.
- Whether all adult humans actually possess dormant third-generation tooth buds, or only a subset. The evidence base is stronger for people with congenital tooth agenesis than for the general population.
- The exact start date of the trial (sources report September vs. October 2024). ---
Sources
3 of 5 linked to recordsMurashima-Suginami et al., "Anti-USAG-1 therapy for tooth regeneration through enhanced BMP signaling," Science Advances (2021)
"Development of a new antibody drug to treat congenital tooth agenesis," ScienceDirect / Regenerative Therapy (2024)
USAG-1 and Regenerative Dentistry review (PMC12867463)
Medical Xpress / AFP reporting on Kyoto trial
Concierge Dental / Oral Health Group summaries of trial protocol